Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, Jeffrey A., Kim, Kevin B., Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Li, Jiang, Nolop, Keith B., Lee, Richard J., Joe, Andrew K., Ribas, Antoni·2012·New England Journal of Medicine
DOI 10.1056/nejmoa1112302

Cited by (1,003)

Items 401–500 of 1,003

  1. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
    Aoxue Wang, Xiaoyi Qi · 2013 · IUBMB Life
  2. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)
    Su Jin Lee, Tae Min Kim, Yu Jung Kim, Kee‐Taek Jang, Hyo Jin Lee, Soon Nam Lee, Mi Sun Ahn, In Gyu Hwang, Suee Lee, MoonHee Lee et al. · 2015 · The Oncologist
  3. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma
    Zeynep Eroglu, Y. Ann Chen, Geoffrey Thomas Gibney, Jeffrey S. Weber, Ragini Reiney Kudchadkar, Nikhil I. Khushalani, Joseph Markowitz, Andrew Scott Brohl, Leticia F. Tetteh, Howida Ramadan et al. · 2018 · Clinical Cancer Research
  4. Vemurafenib
    Claus Garbe, Thomas Eigentler · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  5. Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
    López-Cobo, Sheila, Pieper, Natalia, Campos-Silva, Carmen, García-Cuesta, Eva M., Reyburn, Hugh T., Paschen, Annette, Valés-Gómez, Mar · 2018 · OncoImmunology
  6. Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
    Melanie Sweetlove, Emma Wrightson, Sharada Kolekar, Gordon W. Rewcastle, Bruce C. Baguley, Peter Robin Shepherd, Stephen M. F. Jamieson · 2015 · Frontiers in Oncology
  7. Molecular and genetic diversity in the metastatic process of melanoma
    Katja Harbst, Martin Lauss, Helena Cirenajwis, Christof Winter, Jillian Howlin, Therese Törngren, Anders Kvist, Björn Nodin, Eleonor Olsson, Jari Häkkinen et al. · 2014 · The Journal of Pathology
  8. Phase II trial of vorinostat in advanced melanoma
    Naomi Balzer Haas, Ian C. Quirt, Sebastién J. Hotte, Elaine McWhirter, R. Polintan, Samuel Litwin, Peter D. Adams, Tony McBryan, L. Wang, Lainie P. Martin et al. · 2014 · Investigational New Drugs
  9. Nras in melanoma: Targeting the undruggable target
    Mario Mandalà, Barbara Merelli, Daniela Massi · 2014 · Critical Reviews in Oncology/Hematology
  10. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
    Chelsea Ma, April Wang Armstrong · 2013 · Journal of Dermatological Treatment
  11. BRAF VE1 Immunoreactivity Patterns in Epithelioid Glioblastomas Positive for BRAF V600E Mutation
    Bette Kay Kleinschmidt-DeMasters, Dara L. Aisner, Nicholas K. Foreman · 2015 · The American Journal of Surgical Pathology
  12. The presentation and outcomes of mucosal melanoma in 695 patients
    Neeraja Konuthula, Mohemmed Nazir Khan, Arjun K. Parasher, Anthony Del Signore, Eric M. Genden, Satish Govindaraj, Alfred Marc Iloreta · 2016 · International Forum of Allergy & Rhinology
  13. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
    Weibin Wang, Helen H. Kang, Yinu Zhao, Irene M. Min, Brian Wyrwas, Maureen D. Moore, Lisong Teng, Rasa Zarnegar, Xuejun Jiang, Thomas J. Fahey · 2016 · The Journal of Clinical Endocrinology & Metabolism
  14. 18F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker
    Jason R. Young, Geoffrey Bates Johnson, Robert C. Murphy, Ronald S. Go, Stephen M. Broski · 2017 · Journal of Nuclear Medicine
  15. Selective RAF inhibitor impairs ERK 1/2 phosphorylation and growth in mutant NRAS , vemurafenib‐resistant melanoma cells
    Kaitlyn Le, Erik Scott Blomain, Ulrich Rodeck, Andrew E. Aplin · 2013 · Pigment Cell & Melanoma Research
  16. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
    ADIL I. DAUD, Harriet M. Kluger, Razelle Kurzrock, Frauke Schimmöller, Aaron Weitzman, Thomas A. Samuel, Ali H. Moussa, Michael S. Gordon, Geoffrey Ira Shapiro · 2017 · British Journal of Cancer
  17. Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies
    Cristian Scatena, Daniela Murtas, Sara Tomei · 2021 · Frontiers in Oncology
  18. Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?
    Mónica Arnedos, Jean‐Charles Soria, Fabrice André, Thomas Tursz · 2014 · Cancer Treatment Reviews
  19. Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma
    Camila S. Oliveira, Charles Edo de Bock, Timothy J. Molloy, Elham Sadeqzadeh, Xin Geng, Peter Hersey, Xu Dong Zhang, Rick Francis Thorne · 2014 · BMC Cancer
  20. Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
    Monica Marzagalli, Marina Montagnani Marelli, Lavinia Casati, Fabrizio Fontana, Roberta Manuela Moretti, Patrízia Limonta · 2016 · Frontiers in Endocrinology
  21. Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ
    Laura J. Vella, Andreas Behren, Bradley M. Coleman, David W. Greening, Andrew Francis Hill, Jonathan Simon Cebon · 2017 · Neoplasia
  22. Innovation in oncology clinical trial design
    Jaap Verweij, Hans R. Hendriks, H. Zwierzina, Hanauske, Volker Wacheck, Olivier Collignon, Paolo Bruzzi, J. Gross, Todd Riehl, Frank Bretz et al. · 2019 · Cancer Treatment Reviews
  23. MEK inhibition in non-small cell lung cancer
    Stinchcombe, Thomas E., Johnson, Gary L. · 2014 · Lung Cancer
  24. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
    Maria E. Cabanillas, Ami P. Patel, Brian P. Danysh, Ramona Dadu, Scott Kopetz, Gerald Steven Falchook · 2014 · Hormones and Cancer
  25. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
    Matteo Salvatore Carlino, Georgina Venetia Long, Richard F. Kefford, Helen Rizos · 2015 · Critical Reviews in Oncology/Hematology
  26. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
    Yongping Shao, Andrew E. Aplin · 2012 · Cell Death and Differentiation
  27. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations
    Meriem Chraybi, Issam Abd Alsamad, Christiane Copie‐Bergman, Maryse Baia, Jocelyne André, Nicolas Dumaz, Nicolás Ortonne · 2013 · Human Pathology
  28. Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014
    Gary B. Deutsch, Devin C. Flaherty, Daniel D. Kirchoff, Mariel Bailey, Sarah Vitug, Leland Jay Foshag, Mark B. Faries, Anton J. Bilchik · 2017 · JAMA Surgery
  29. Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas
    Johanne Lade‐Keller, Kirsten M. Rømer, Per Guldberg, Rikke Riber‐Hansen, Lise Lotte Hansen, Torben Steiniche, Henrik Hager, Lasse S. Kristensen · 2012 · Journal of Molecular Diagnostics
  30. Reengineered tricyclic anti-cancer agents
    David B. Kastrinsky, Jaya Sangodkar, Nilesh Zaware, Sudeh Izadmehr, Neil S. Dhawan, Goutham Narla, Michael H. J. Ohlmeyer · 2015 · Bioorganic & Medicinal Chemistry
  31. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness
    Emi Y. Tokuda, Jennifer L. Leight, Kristi S. Anseth · 2014 · Biomaterials
  32. BRIM-1, -2 and -3 Trials: Improved Survival with Vemurafenib in Metastatic Melanoma Patients with a BRAF V600E Mutation
    Kate Young, Anna Rachel Minchom, James Larkin · 2012 · Future Oncology
  33. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
    Bjoern Titz, Anastasia Lomova, Allison Le, Willy Hugo, Xiangju Kong, Johanna ten Hoeve, Michael Friedman, Hubing Shi, Gatien Moriceau, Chunying Song et al. · 2016 · Cell Discovery
  34. Liquid Biopsy: From Basic Research to Clinical Practice
    Mónica Macías, Estíbaliz Alegre, Ángel Díaz‐Lagares, Ana Patiño‐García, José Luis Perez‐Gracia, Miguel F. Sanmamed, Rafael López‐López, Nerea Varo, Álvaro González · 2017 · Advances in clinical chemistry
  35. A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF V600E-Mutant Brain Tumor
    Jiawan Wang, Zhan Yao, Philip Jonsson, Amy N. Allen, Alice Can Ran Qin, Sharmeen Uddin, Ira J. Dunkel, Mary Petriccione, Katia Manova, Sofia S. Haque et al. · 2018 · Cancer Discovery
  36. Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter
    Redmer, Torben · 2018 · Molecular Cancer
  37. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care
    Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Vito Vanella, Marco Palla, Paolo A. Ascierto · 2017 · BioDrugs
  38. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
    Parvez M. Lokhandwala, Li‐Hui Tseng, Erika F. Rodriguez, Gang Zheng, Aparna Pallavajjalla, Christopher D. Gocke, James R. Eshleman, Ming‐Tseh Lin · 2019 · BMC Cancer
  39. Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients
    Davide Zocco, Simona Bernardi, Mauro Novelli, Chiara Astrua, Paolo Fava, Nataša Zarovni, Francesco M. Carpi, Laura Bianciardi, Ottavia Malavenda, Pietro Quaglino et al. · 2020 · Scientific Reports
  40. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower, Yisong Wang, Giuseppe Giaccone · 2014 · Journal of Molecular Medicine
  41. Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
    Catherine Belle Meador, Christine Micheel, Mia Alyce Levy, Christine Marie Lovly, Leora Horn, Jeremy Lyle Warner, Douglas Buckner Johnson, Zhongming Zhao, Ingrid A. Anderson, Jeffrey Alan Sosman et al. · 2014 · Clinical Cancer Research
  42. Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma
    Claudia Capparelli, Sheera R. Rosenbaum, Adam C. Berger, Andrew E. Aplin · 2015 · Journal of Biological Chemistry
  43. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
    Matteo Salvatore Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan M. Nagrial, Richard A. Scolyer, Richard F. Kefford, Georgina Venetia Long et al. · 2014 · Clinical Cancer Research
  44. Clinical Pharmacokinetics of Vemurafenib
    Weijiang Zhang, Dominik Heinzmann, Joseph F. Grippo · 2017 · Clinical Pharmacokinetics
  45. Metastasis Awakening: The challenges of targeting minimal residual cancer
    Bernhard Michael Polzer, Christoph A. Klein · 2013 · Nature Medicine
  46. Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy
    Marie Perier‐Muzet, Luc Thomas, Nicolas Poulalhon, Sébastien Debarbieux, Pierre‐Paul Bringuier, Gérard Duru, Lauriane Depaepe, B. Balme, Stéphane Dalle · 2013 · Journal of Investigative Dermatology
  47. Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma
    Sapna Pradyuman Patel, Alexander J. Lazar, Nicholas E. Papadopoulos, Ping Liu, Jeffrey R. Infante, Michelle R. Glass, Carol Vaughn, Patricia Mucci LoRusso, Roger B. Cohen, Michael A. Davies et al. · 2012 · Cancer
  48. Conjunctival Melanoma: Current Treatments and Future Options
    Joseph M. Grimes, Nirav V. Shah, Faramarz H. Samie, Richard D. Carvajal, Brian P. Marr · 2020 · American Journal of Clinical Dermatology
  49. Prevalence of BRAF V600 in glioma and use of BRAF Inhibitors in patients with BRAF V600 mutation-positive glioma: systematic review
    Lily Andrews, Zak A Thornton, Saanwalshah Samir Saincher, Ian Y Yao, Sarah Dawson, Luke A. McGuinness, Hayley E. Jones, Sarah Jefferies, Susan C Short, Hung‐Yuan Cheng et al. · 2021 · Neuro-Oncology
  50. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
    Samra Turajlic, Simon J. Furney, Gordon Stamp, Sareena Rana, Gerda Ricken, Y. Oduko, Grazia Saturno, Caroline J. Springer, A. Hayes, Martin Eric Gore et al. · 2014 · Annals of Oncology
  51. Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
    Abdelali Lehraiki, Michaël Cerezo, Florian Rouaud, Patricia Abbe, M Allegra, Jérôme Kluza, Philippe Marchetti, Véronique Imbert, Yann Chéli, Corine Bertolotto et al. · 2015 · Cell Discovery
  52. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
    Julia Wilkerson, Kald A. Abdallah, Charles Hugh-Jones, Greg Curt, Mace L. Rothenberg, Ronit Simantov, Martin Murphy, Joseph Morrell, Joel Beetsch, Daniel J. Sargent et al. · 2016 · The Lancet Oncology
  53. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma
    Nikki Rae Adler, Rory S Wolfe, John William Kelly, Andrew Mark Haydon, Grant A. McArthur, Catriona McLean, Victoria Mar · 2017 · British Journal of Cancer
  54. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations
    Vincent Pillonel, Darius Juškevičius, Charlotte K.Y. Ng, Andrea Bodmer, Andreas Zettl, David Jucker, Stefan Dirnhofer, Alexandar Tzankov · 2018 · Leukemia
  55. CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
    Roberto Andres Salas Fragomeni, Hye Won Chung, Yosef Landesman, William T. Senapedis, Jean‐Richard Saint‐Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael G. Kauffman, James C. Cusack · 2013 · Molecular Cancer Therapeutics
  56. Recent developments in the medical and surgical treatment of melanoma
    Vita Saranga‐Perry, Chenwi M. Ambe, Jonathan S. Zager, Ragini Reiney Kudchadkar · 2014 · CA A Cancer Journal for Clinicians
  57. 18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis
    Powell Perng, Charles V. Marcus, Rathan M. Subramaniam · 2015 · American Journal of Roentgenology
  58. Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations
    Jennifer J. Wheler, J. Jack Lee, Razelle Kurzrock · 2014 · Cancer Research
  59. Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
    Bilgen Gençler, Müzeyyen Gönül · 2016 · Dermatology Research and Practice
  60. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
    Atul Kulkarni, Husam Al-hraishawi, Srilatha R. Simhadri, Kim Marie Hirshfield, Suzie Chen, Sharon R. Pine, Chandrika Jeyamohan, Levi O. Sokol, Siraj Mahamed Ali, Man Lung Teo et al. · 2017 · Clinical Cancer Research
  61. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases
    Kamran A. Ahmed, Jessica M. Freilich, Sarah Sloot, Nicholas B. Figura, Geoffrey Thomas Gibney, Jeffrey S. Weber, Siriporn Sarangkasiri, Prakash Chinnaiyan, Peter A. Forsyth, Arnold B. Etame et al. · 2014 · Journal of Neuro-Oncology
  62. Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib
    Holger Andreas Haenssle, Sophie Luise Kraus, Franziska Brehmer, Lutz Kretschmer, Bernward Völker, Hiba Asper, Alexander Kapp, Ralf Gutzmer · 2012 · Archives of Dermatology
  63. Management of regional metastatic disease in head and neck cutaneous malignancy.1. Cutaneous squamous cell carcinoma
    Ben Gurney, Carrie Newlands · 2014 · British Journal of Oral and Maxillofacial Surgery
  64. The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
    Brijal M. Desai, Jessie Villanueva, Thierry-Thien K. Nguyen, Mercedes Lioni, Min Xiao, Jun Kong, Clemens Krepler, Adina Vultur, Keith T. Flaherty, Katherine L. Nathanson et al. · 2013 · PLoS ONE
  65. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
    Drew C. Deniger, Mei Li M. Kwong, Anna Pasetto, Mark E. Dudley, John R. Wunderlich, Michelle M. Langhan, Chyi‐Chia Richard Lee, Steven A. Rosenberg · 2016 · Clinical Cancer Research
  66. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
    Andreas N. WICKI, Mario Mandalà, Daniela Massi, Daniela Taverna, Huifang Tang, Brian A. Hemmings, Gongda Xue · 2016 · Physiological Reviews
  67. Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    Bruce J. Roth, Lada Krilov, Sylvia Adams, Carol A Aghajanian, Peter Brian Bach, Fadi Braiteh, Marcia S. Brose, Lee M. Ellis, Harry Paul Erba, Daniel J. George et al. · 2012 · Journal of Clinical Oncology
  68. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
    Mohamed Alaa Gouda, Blessie Elizabeth Nelson, Lars Buschhorn, Adam Wahida, Vivek Subbiah · 2023 · Clinical Cancer Research
  69. Melanoma biology and treatment: a review of novel regulated cell death-based approaches
    Ming-yun Hsieh, Sheng‐Kai Hsu, Tzu‐Yu Liu, Chang‐Yi Wu, Chien‐Chih Chiu · 2024 · Cancer Cell International
  70. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
    Richard Wayne Joseph, Abhisek Swaika, Jennifer A. Crozier · 2014 · Drug Design Development and Therapy
  71. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
    Dennis A. Revicki, Alfons J.M. van den Eertwegh, Paul C. Lorigan, Célèste Lebbé, Gerald P. Linette, Christian H. H. Ottensmeier, Shima Safikhani, MARIANNE E. MESSINA, Axel Hoos, Samuel Wagner et al. · 2012 · Health and Quality of Life Outcomes
  72. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity
    Charles H. Adelmann, Grace Ching, Lili Du, Rachael C Saporito, Varun Vivek Bansal, Lindy J. Pence, Roger J. Liang, Woojin Lee, Kenneth Yee Tsai · 2016 · Oncotarget
  73. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications
    Daniel H. Ahn, Tanios Bekaii‐Saab · 2017 · Journal of Gastrointestinal Oncology
  74. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
    Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo A. Ascierto, Stefano Cascinu, Jürgen Christian Becker, Axel Hauschild, Antonella Romanini, Riccardo Danielli, Reinhard Dummer et al. · 2019 · Cancer Immunology Immunotherapy
  75. A Review of Novel Therapies for Melanoma
    Chanté Karimkhani, Rene C. Gonzalez, Robert Paul Dellavalle · 2014 · American Journal of Clinical Dermatology
  76. BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
    James S. Wilmott, Alexander Maxwell Menzies, Lauren Elaine Haydu, David Capper, Matthias Preusser, Ying E. Zhang, John F. Thompson, Richard F. Kefford, Andreas von Deimling, Richard A. Scolyer et al. · 2013 · British Journal of Cancer
  77. Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
    Kathrin Heinrich, Lisa Miller‐Phillips, Frank Ziemann, Korbinian Hasselmann, Katharina Rühlmann, Madeleine Flach, Dorottya Biro, Michael von Bergwelt‐Baildon, Julian Walter Holch, Tobias Herold et al. · 2022 · Journal of Cancer Research and Clinical Oncology
  78. The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies
    Saber İmani, Ghazaal Roozitalab, Mahdieh Emadi, Atefeh Moradi, Payam Behzadi, Parham Jabbarzadeh Kaboli · 2024 · Frontiers in Oncology
  79. HSP105 Recruits Protein Phosphatase 2A To Dephosphorylate β-Catenin
    Nancy Yu, Michael Kakunda, Victoria C. Pham, Jennie Rebecca Lill, Pan Du, Matthew J. Wongchenko, Yibing Yan, Ron Firestein, XiaoDong Huang · 2015 · Molecular and Cellular Biology
  80. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
    James Larkin, Fisher · 2012 · Cancer Management and Research
  81. The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors
    Julia A. Bridge · 2014 · Modern Pathology
  82. Value of positron emission tomography scan in stage III cutaneous melanoma: A systematic review and meta-analysis
    Angel M. Rodriguez-Rivera, Haytham H. Alabbas, Aliya Ramjaun, Ari‐Nareg Meguerditchian · 2014 · Surgical Oncology
  83. RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma
    Thibault Houlès, Simon‐Pierre Gravel, Geneviève Lavoie, Sejeong Shin, Mathilde Savall, Antoine Méant, Benoı̂t Grondin, Louis Arthur Gaboury, Sang-Oh Yoon, Julie St‐Pierre et al. · 2018 · Cancer Research
  84. The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be
    Ryan Joseph Sullivan, Patricia Mucci LoRusso, Keith T. Flaherty · 2013 · Clinical Cancer Research
  85. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
    Antonio Giovanni Solimando, Matteo Da Vià, Sebastiano Cicco, Patrizia Leone, Giuseppe Di Lernia, Donato Giannico, Vanessa Desantis, Maria Antonia Frassanito, Arcangelo Morizio, Julia Delgado Tascon et al. · 2019 · Journal of Clinical Medicine
  86. Immunomodulatory therapy for melanoma: Ipilimumab and beyond
    Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2013 · Clinics in Dermatology
  87. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study
    Collette McCourt, Helen G. Coleman, Liam Murray, Marie M. Cantwell, O.M. Dolan, Des G. Powe, Chris R. Cardwell · 2014 · British Journal of Dermatology
  88. Current Staging and Prognostic Factors in Melanoma
    Edmund K. Bartlett, Giorgos Constantine Karakousis · 2015 · Surgical Oncology Clinics of North America
  89. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
    Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy H. Guthrie, Sajeve Samuel Thomas, Steven J O'Day, Montaser F. Shaheen, Bin Zhang, Stephen Francis et al. · 2016 · Journal for ImmunoTherapy of Cancer
  90. Metastatic pathways in patients with cutaneous melanoma
    Nikki Rae Adler, Andrew Mark Haydon, Catriona McLean, John William Kelly, Victoria Mar · 2016 · Pigment Cell & Melanoma Research
  91. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema
    Caroline A. Gjorup, Mogens Grøenvold, Helle Westergren Hendel, Karin Dahlstrøm, Krzysztof T. Drzewiecki, Tobias Wirenfeldt Klausen, Lisbet Rosenkrantz Hölmich · 2017 · European Journal of Cancer
  92. Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
    Stephanie A. Toll, Hung N. Tran, Jennifer A. Cotter, Alexander Russell Judkins, Benita Tamrazi, Jaclyn A. Biegel, Girish Dhall, Nathan John Robison, Kaaren Waters, Palak G. Patel et al. · 2019 · Oncotarget
  93. Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model
    Kirouac, Daniel C., Schaefer, Gabriele, Chan, Jocelyn, Merchant, Mark, Orr, Christine, Huang, Shih-Min A., Moffat, John, Liu, Lichuan, Gadkar, Kapil, Ramanujan, Saroja · 2017 · npj Systems Biology and Applications
  94. Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility
    Cristi Marin, Alain Beauchet, David Capper, Ute S. Zimmermann, Catherine Julié, Marius Ilié, Philippe Saïag, Andreas von Deimling, Paul M Hofman, Jean‐François Emile · 2013 · Archives of Pathology & Laboratory Medicine
  95. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma
    Lili Yue, Zhiming Huang, Stephen Fong, Stanley P. L. Leong, James G. Jakowatz, Alexandra Charruyer, Maria L. Wei, Ruby Ghadially · 2015 · Melanoma Research
  96. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy
    Sangeetha Meda Reddy, Alexandre Reuben, Jennifer Ann Wargo · 2016 · Current Oncology Reports
  97. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
    Bhargavi Pulluri, Abhijeet Kumar, Montaser F. Shaheen, Joanne Jeter, Srinath Sundararajan · 2017 · Pharmacological Research
  98. Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
    Sara Touhami, Isabelle S. Audo, C. Terrada, Alain Gaudric, Phuc LeHoang, Valérie Touitou, Bahram Bodaghi · 2019 · Progress in Retinal and Eye Research
  99. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
    James J. Harding, Federica Catalanotti, Rodrigo Ramella Munhoz, Donavan T. Cheng, Amin Yaqubie, Nicole E. Kelly, Gregory C McDermott, Romona Kersellius, Taha Merghoub, Mario E. Lacouture et al. · 2015 · The Oncologist
  100. Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
    Adarsh Vennepureddy, Nishitha Thumallapally, Vijeyaluxmy Motilal Nehru, Jean Paul Atallah, Terenig O. Terjanian · 2015 · Journal of Clinical Medicine Research